
Citation: Murtaza Shabbir Hussain, Gabriel M Rodriguez, Difeng Gao, Michael Spagnuolo, Lauren Gambill, Mark Blenner. Recent advances in bioengineering of the oleaginous yeast Yarrowia lipolytica[J]. AIMS Bioengineering, 2016, 3(4): 493-514. doi: 10.3934/bioeng.2016.4.493
[1] | Jiying Ma, Wei Lin . Dynamics of a stochastic COVID-19 epidemic model considering asymptomatic and isolated infected individuals. Mathematical Biosciences and Engineering, 2022, 19(5): 5169-5189. doi: 10.3934/mbe.2022242 |
[2] | Ahmed Alshehri, Saif Ullah . A numerical study of COVID-19 epidemic model with vaccination and diffusion. Mathematical Biosciences and Engineering, 2023, 20(3): 4643-4672. doi: 10.3934/mbe.2023215 |
[3] | Abdallah Alsammani, Calistus N. Ngonghala, Maia Martcheva . Impact of vaccination behavior on COVID-19 dynamics and economic outcomes. Mathematical Biosciences and Engineering, 2025, 22(9): 2300-2338. doi: 10.3934/mbe.2025084 |
[4] | Pannathon Kreabkhontho, Watchara Teparos, Thitiya Theparod . Potential for eliminating COVID-19 in Thailand through third-dose vaccination: A modeling approach. Mathematical Biosciences and Engineering, 2024, 21(8): 6807-6828. doi: 10.3934/mbe.2024298 |
[5] | Tianfang Hou, Guijie Lan, Sanling Yuan, Tonghua Zhang . Threshold dynamics of a stochastic SIHR epidemic model of COVID-19 with general population-size dependent contact rate. Mathematical Biosciences and Engineering, 2022, 19(4): 4217-4236. doi: 10.3934/mbe.2022195 |
[6] | Shina D. Oloniiju, Olumuyiwa Otegbeye, Absalom E. Ezugwu . Investigating the impact of vaccination and non-pharmaceutical measures in curbing COVID-19 spread: A South Africa perspective. Mathematical Biosciences and Engineering, 2022, 19(1): 1058-1077. doi: 10.3934/mbe.2022049 |
[7] | Anthony Morciglio, R. K. P. Zia, James M. Hyman, Yi Jiang . Understanding the oscillations of an epidemic due to vaccine hesitancy. Mathematical Biosciences and Engineering, 2024, 21(8): 6829-6846. doi: 10.3934/mbe.2024299 |
[8] | Fang Wang, Lianying Cao, Xiaoji Song . Mathematical modeling of mutated COVID-19 transmission with quarantine, isolation and vaccination. Mathematical Biosciences and Engineering, 2022, 19(8): 8035-8056. doi: 10.3934/mbe.2022376 |
[9] | Yujie Sheng, Jing-An Cui, Songbai Guo . The modeling and analysis of the COVID-19 pandemic with vaccination and isolation: a case study of Italy. Mathematical Biosciences and Engineering, 2023, 20(3): 5966-5992. doi: 10.3934/mbe.2023258 |
[10] | Tetsuro Kobayashi, Hiroshi Nishiura . Prioritizing COVID-19 vaccination. Part 2: Real-time comparison between single-dose and double-dose in Japan. Mathematical Biosciences and Engineering, 2022, 19(7): 7410-7424. doi: 10.3934/mbe.2022350 |
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus which can lead to severe sequelae or death due to breathing difficulties, headaches and loss of taste or smell [1,2]. Since the outbreak of COVID-19 in 2019, it has seriously affected the development of society and people's lives all over the world. In order to control COVID-19 as soon as possible, mathematical researchers have studied the infectious disease by establishing mathematical models for COVID-19 and analyzed their dynamical behavior[3,4,5,6,7,8].
The mathematical model of infectious disease was first proposed by Kermack and McKendrick[9]. They considered a fixed population with only three parts, i.e., SIR: the susceptible population S(t), the infected population I(t) and the recovery population R(t). Since then, many improved models, such as SEIR and SIRS models, have been used to describe various properties and laws of disease transmission[10,11,12,13,14,15]. Batabyal[16] built an SEIR model based on the seasonal transmission nature of the virus, analyzed the stability of the model and obtained the influence of the parameters on the basic regeneration number. Gumel et al.[17] proposed extended models of the infectious disease in which the stability of the equilibrium point and parameter estimation was studied. The global properties of an SIR model with nonlocal disperse and immigration effects were studied in [18]; they evaluated the persistence, extinction of the disease, global stability analysis of the model, existence of the positive equilibrium state and its uniqueness. The above deterministic models have well revealed the mechanism of infectious diseases. In fact, due to the disturbance of uncertain factors such as the environment, temperature, virus variation, prevention and control measures, the COVID-19 model with random factors has gradually attracted more and more attention[19,20,21,22,23]. Sweilam et al.[24] considered environmental noise and fractional calculus in the COVID-19 model which concluded that random factors have a considerable impact on the demise of infection. In a stochastic SIQ model affected by white noise, the sufficient conditions for stable distribution and disease extinction were proved by Din et al.[25]. Khan et al.[26] described a stochastic SEQIR model disturbed by white noise and telegraph noise at the same time; the uniqueness of global positive solutions and random thresholds was obtained. The stochastic coronavirus disease model with jump diffusion has also been researched, and Tesfay et al.[27] found that random disturbance can inhibit the outbreak of disease better than the deterministic model.
As we all know, vaccination can improve the level of immunity of the population and control the spread of the epidemic[28,29,30,31]. Djilali and Bentout[32] investigated an SVIR system with distributed delay and drew the conclusion that increasing the number of people vaccinated will reduce the spread of the disease. Zhang et al. [33] proposed a stochastic SVIR model based on one vaccination and got the sufficient conditions for the existence of non-trivial periodic solutions. A basic qualitative analysis of the positivity, invariant region and stability of disease-free equilibrium points was performed for a stochastic SVITR model with vaccination[34]. Wang et al.[35] constructed a stochastic COVID-19 mathematical model with quarantine, isolation and vaccination; they also studied the influence of vaccination rates, vaccine effectiveness and immune loss rates on COVID-19. Omar et al.[36] studied a discrete time-delayed influenza model with two strains and two vaccinations, and then concluded that the vaccination of one strain would affect the disease dynamics of the other strain. Alshaikh[37] generated a fractional order stochastic model based on the secondary vaccination and analyzed various vaccination strategies. With the development of current medical technology and research, more and more of the population has completed a secondary vaccination, even the third vaccination. Based on the above references, although there have been extensive studies and application of COVID-19, it should be pointed out that the complexity modeling of COVID-19 is still not enough, and that the mechanisms of transmission for the complex model are unclear. Based on this, the research on the transmission dynamics characteristics of stochastic COVID-19 epidemics with secondary vaccination is very necessary.
In this paper, a stochastic disease model with secondary vaccination is established in Section 2. In Section 3, we apply random Lyapunov function theory to study the qualitative characteristics. In the last section, numerical simulations are applied to verify the theoretical results.
In this study, we divided the population into seven time-dependent categories and built a mathematical model of COVID-19 with secondary vaccination (see Figure 1) based on the current situation of the epidemic. That is, it includes the susceptible person S(t), exposed person E(t), first vaccinator V1(t), second vaccinator V2(t), asymptomatic infected person A(t), symptomatic infected person I(t) and recovering person R(t).
In order to obtain the required results, we present the following assumptions:
1) The recovered population has immunity and will not be infected again.
2) Most people who receive the second vaccination will have immunity and will not be infected again.
3) Vaccinated people will transfer to exposure after being infected.
4) Assuming that the interval between two vaccinations is short, the first vaccinated person will not be infected temporarily.
The model is shown in Eq (2.1):
{dSdt=Λ−β1SA−β2SI−μ1S−ρ1S,dEdt=β1SA+β2SI+α2β2V2I−σE−μ1E,dV1dt=ρ1S−ρ2V1−μ1V1,dV2dt=ρ2V1−μ1V2−α2β2V2I−(1−α2)V2,dAdt=(1−ω)σE−αA−γ1A−(μ1+μ2)A,dIdt=ωσE+αA−γ2I−(μ1+μ2)I,dRdt=(1−α2)V2+γ1A+γ2I−μ1R, | (2.1) |
where Λ is the constant migration rate of the susceptible population, β1 is the transmission rate of asymptomatic infected persons, β2 is the transmission rate of symptomatic infected persons, ρ1 is the first vaccination rate, ρ2 is the second vaccination rate, σ is the infection rate of the exposed to the infected, ω is the proportion of infections in symptomatic patients, α is the ratio of asymptomatic infected people to symptomatic infected people and α2 (0<α2<1) is the ratio of secondary vaccinators to symptomatic infected people, so 1−α2 is the effectiveness of the vaccine. γ1 and γ2 respectively represent the recovery rate of asymptomatic and symptomatic infected persons. μ1 and μ2 represent the natural mortality rate and disease-related mortality rate respectively. All parameters are positive.
The disease-free equilibrium point of Eq (2.1) can be obtained (E,A and I are all zero)
P0=(S∗,0,V∗1,V∗2,0,0,R∗), |
where
S∗=Λμ1+ρ1,V∗1=Λρ1(μ1+ρ1)(μ1+ρ2),V∗2=Λρ1ρ2(μ1+ρ1)(μ1+ρ2)(μ1+1−α2),R∗=Λρ1ρ2(1−α2)μ1(μ1+ρ1)(μ1+ρ2)(μ1+1−α2). |
Using the next generation matrix method[17], the basic regeneration number of Eq (2.1) is
R0=[Λβ1μ1+ρ1+Λα2β2ρ1ρ2(μ1+ρ1)(μ1+ρ2)(μ1+1−α2)](α+ωσ(γ1+μ1+μ2)(σ+μ1)(α+γ1+μ1+μ2)(γ2+μ1+μ2))−(1−ω)σ(σ+μ1)(α+γ1+μ1+μ2). |
As we all know, the following theoretical results on equilibrium stability have been established[1]:
1) when R0<1, the disease-free equilibrium point of the infectious disease model is locally asymptotically stable; otherwise, it is unstable;
2) when R0=1, the infectious model passes through a transcritical bifurcation near the disease-free equilibrium.
In fact, in order to have a more accurate understanding of the real disease development process, we added the influence of random factors into Eq (2.1). The improved stochastic model SEV1V2AIR is as follows:
{dS=[Λ−β1SA−β2SI−(μ1+ρ1)S]dt+σ1dB1(t),dE=[β1SA+β2SI+α2β2V2I−(σ+μ1)E]dt+σ2dB2(t),dV1=[ρ1S−(ρ2+μ1)V1]dt+σ3dB3(t),dV2=[ρ2V1−μ1V2−α2β2V2I−(1−α2)V2]dt+σ4dB4(t),dA=[(1−ω)σE−(α+γ1+μ1+μ2)A]dt+σ5dB5(t),dI=[ωσE+αA−(γ2+μ1+μ2)I]dt+σ6dB6(t),dR=[(1−α2)V2+γ1A+γ2I−μ1R]dt+σ7dB7(t), | (2.2) |
where Bi(t),i=1,2,3,⋯,7 is the independent standard Brownian motion which represents small disturbance on each variable, and σi≥0 is the intensity of Bi(t),i=1,2,3,⋯,7.
In order to study the dynamical behavior of the infectious disease model proposed in this paper, we first need to consider whether the solution is global and non-negative. So in this section, we will prove that there exists a unique global positive solution for Eq (2.2).
Theorem 1. For any given initial value {S(0),E(0),V1(0),V2(0),A(0),I(0),R(0)}∈R7+, Eq (2.2) has a unique positive solution {S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)} at t≥0, and this solution will stay in R7+ with a probability of 1. So, for all t≥0, the solution {S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)}∈R7+ a.s.
Proof: Since the coefficients of the equation are Lipschitz continuous, for any given initial value {S(0),E(0),V1(0),V2(0),A(0),I(0),R(0)}∈R7+, there is a unique local solution {S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)},t∈[0,τe), where τe stands for the explosion time, and if τe=∞, this local solution is global. To do that, we have to make k0 sufficiently large and S(t), E(t), V1(t), V2(t), A(t), I(t), R(t) is in the interval [1k0,k0]. For each integer k≥k0, we define the stopping time as follows:
τk=inf{t∈[0,τe):S(t)∉(1k,k)orE(t)∉(1k,k)orV1(t)∉(1k,k)=orV2(t)∉(1k,k)orA(t)∉(1k,k)orI(t)∉(1k,k)orR(t)∉(1k,k)}. |
In this section, we set inf∅=∞ (∅ denotes the empty set). It is easy to get τk that is increasing as k→∞. Set τ∞=limk→∞τk which implies τ∞<τk a.s.. If the hypothesis τ∞<∞ is true, then τe=∞ a.s. For all t≥0, this means
{S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)}∈R7+ a.s. |
In other words, we just prove τe=∞ a.s. If this statement is wrong, then there are constants T>0 and ε∈(0,1) which make P{τ∞<T}>ε. Hence there is an integer k1>k0 such that
P{τ∞≤T}≥ε, ∀k>k1. | (3.1) |
Define a C2−function V:R7+→R+ as follows:
V(S,E,V1,V2,A,I,R)=(S−1−lnS)+(E−1−lnE)+(V1−1−lnV1)+(V2−1−lnV2)+(A−1−lnA)+(I−1−lnI)+(R−1−lnR); | (3.2) |
the non-negativity of Eq (3.2) can be obtained from
u−1−lnu≥0, ∀u>0. |
Using Itˆos formula, we can get
dV(S,E,V1,V2,A,I,R)=LV(S,E,V1,V2,A,I,R)dt+σ1(S−1)dB1(t)+σ2(E−1)dB2(t)+σ3(V1−1)dB3(t)+σ4(V2−1)dB4(t)+σ5(A−1)dB5(t)+σ6(I−1)dB6(t)+σ7(R−1)dB7(t), | (3.3) |
where LV:R7+→R+ is defined by
LV(S,E,V1,V2,A,I,R)=(1−1S)[Λ−β1SA−β2SI−(μ1+ρ1)S]+(1−1E)[β1SA+β2SI+α2β2V2I−(σ+μ1)E]+(1−1V1)[ρ1S−(ρ2+μ1)V1]+(1−1V2)[ρ2V1−μ1V2−α2β2V2I−(1−α2)V2]+(1−1A)[(1−ω)σE−(α+γ1+μ1+μ2)A]+(1−1I)[ωσE+αA−(γ2+μ1+μ2)I]+(1−1R)[(1−α2)V2+γ1A+γ2I−μR]+12(σ21+σ22+σ23+σ24+σ25+σ26+σ27)⩽Λ+ρ1+σ+ρ2+(1−α2)+α+γ1+γ2+2μ2+7μ1+(β2(1−α2)−μ1)I+(β1−μ1)A−μ2(A+I)−μ1(S+E+V1+V2+A+I+R)+12(σ21+σ22+σ23+σ24+σ25+σ26+σ27)⩽Λ+σ+ρ1+ρ2+(1−α2)+α+γ1+γ2+2μ1+7μ2+12(σ21+σ22+σ23+σ24+σ25+σ26+σ27)=:K, |
where β2≤max{μ11−α2,μ1} is assumed and K(K∈N+) is a positive constant, which does not rely on S, E, V1, V2, A, I, R and t. So, there is
dV(S,E,V1,V2,A,I,R)⩽Kdt+σ1(S−1)dB1(t)+σ2(E−1)dB2(t)+σ3(V1−1)dB3(t)+σ4(V2−1)dB4(t)+σ5(A−1)dB5(t)+σ6(I−1)dB6(t)+σ7(R−1)dB7(t). | (3.4) |
Let us integrate both sides of Eq (3.4) from 0 to τk∧T=min{τk,T} and then take the expectation; we can get
EV(S(τk∧T),E(τk∧T),V1(τk∧T),V2(τk∧T),A(τk∧T),I(τk∧T),R(τk∧T))⩽V(S(0),E(0),V1(0),V2(0),A(0),I(0),R(0))+KE(τk∧T)⩽V(S(0),E(0),V1(0),V2(0),A(0),I(0),R(0))+KT. | (3.5) |
Set Ωk={τk≤T}, and we obtain P{Ωk}≥ε by Eq (3.1). Now, notice that, for every ω∈Ωk, there is at least one of S(τk,ω), E(τk,ω), V1(τk,ω), V2(τk,ω), A(τk,ω), I(τk,ω) or R(τk,ω) that equals to k or 1k.
Therefore
V{S(τk,ω),E(τk,ω),V1(τk,ω),V2(τk,ω),A(τk,ω),I(τk,ω),R(τk,ω)} |
is no less than
k−1−lnk or 1k−1+lnk; |
thus,
V{S(τk,ω),E(τk,ω),V1(τk,ω),V2(τk,ω),A(τk,ω),I(τk,ω),R(τk,ω)}≥min{k−1−lnk,1k−1+lnk}. | (3.6) |
Substitute Eq (3.5) into Eq (3.6), we have
V(S(0),E(0),V1(0),V2(0),A(0),I(0),R(0))+KT⩾E[1Ωkω∀V{S(τk,ω),E(τk,ω),V(τk,ω),V(τk,ω),A(τk,ω),I(τk,ω),R(τk,ω)}]⩾εmin{k−1−lnk,1k−1+lnk}, | (3.7) |
where 1Ωkω denotes the indicator function of Ωk. Letting k→∞, then
∞>V(S(0),E(0),V1(0),V2(0),A(0),I(0),R(0))+KT=∞. | (3.8) |
Equation (3.8) is a contradiction. Therefore we have τ∞=∞. The proof is completed. Therefore, there exists a unique global positive solution to Eq (2.2).
Lemma 1. For any initial value
{S(0),E(0),V1(0),V2(0),A(0),I(0),R(0)}∈R7+, |
Eq (2.2) always has a unique positive solution
{S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)}∈R7+att≥0, |
{S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)} has the following properties:
limt→∞S(t)t=0,limt→∞E(t)t=0,limt→∞V1(t)t=0,limt→∞V2(t)t=0,limt→∞A(t)t=0,limt→∞I(t)t=0,limt→∞R(t)t=0, | (4.1) |
and
limt→∞logS(t)t⩽0,limt→∞logE(t)t⩽0,limt→∞logV1(t)t⩽0,limt→∞logV2(t)t⩽0,limt→∞logA(t)t⩽0,limt→∞logI(t)t⩽0,limt→∞logR(t)t⩽0, | (4.2) |
as well as
limt→∞∫t0S(x)dB1(x)t=0,limt→∞∫t0E(x)dB2(x)t=0,limt→∞∫t0V1(x)dB3(x)t=0,limt→∞∫t0V2(x)dB4(x)t=0,limt→∞∫t0A(x)dB5(x)t=0,limt→∞∫t0I(x)dB6(x)t=0,limt→∞∫t0R(x)dB7(x)t=0. | (4.3) |
In order to get the conditions of disease extinction, we set Theorem 2.
Theorem 2. Let {S(t),E(t),V1(t),V2(t),A(t),I(t),R(t)}∈R7+ be a positive solution for Eq (2.2), and the initial solution of Eq (2.2) is {S(0),E(0),V1(0),V2(0),A(0),I(0),R(0)}.
If RS0=(1−ω)σΛμ1(α+γ1+μ1+μ2+σ252)<1, then the solution of the system has the following properties:
limt→∞suplogA(t)t<0,limt→∞suplogI(t)t<0. | (4.4) |
Proof: First, integrate Eq (2.2) to obtain
S(t)−S(0)t=Λ−β2⟨S(t)⟩⟨I(t)⟩−β1⟨S(t)⟩⟨A(t)⟩−(μ1+ρ1)⟨S(t)⟩+σ1t∫t0SdB1(x),E(t)−E(0)t=β2⟨S(t)⟩⟨I(t)⟩+β1⟨S(t)⟩⟨A(t)⟩+α2β2⟨V2(t)⟩⟨I(t)⟩−(μ1+σ)⟨E(t)⟩+σ2t∫t0EdB2(x),V1(t)−V1(0)t=ρ1⟨S(t)⟩−(μ1+ρ2)⟨V1(t)⟩+σ3t∫t0V1dB3(x),V2(t)−V2(0)t=ρ2⟨V1(t)⟩−μ1⟨V2(t)⟩−α2β2⟨V2(t)⟩⟨I(t)⟩−(1−α2)⟨V2(t)⟩+σ4t∫t0V2dB4(x),A(t)−A(0)t=(1−ω)σ⟨E(t)⟩−(α+γ1)⟨A(t)⟩−(μ1+μ2)⟨A(t)⟩+σ5t∫t0AdB5(x), | (4.5) |
I(t)−I(0)t=ωσ⟨E(t)⟩+α⟨A(t)⟩−γ2⟨I((t)⟩−(μ1+μ2)⟨I(t)⟩+σ6t∫t0IdB6(x),R(t)−R(0)t=(1−α2)⟨V2(t)⟩+γ1⟨A(t)⟩+γ2⟨I(t)⟩−μ1⟨R(t)⟩+σ7t∫t0RdB7(x). |
Adding the left and right sides of Eq (4.5) respectively, we obtain
S(t)−S(0)t+E(t)−E(0)t+V1(t)−V1(0)t+V2(t)−V2(0)t+A(t)−A(0)t+I(t)−I(0)t+R(t)−R(0)t=A−μ1[⟨S(t)⟩+⟨E(t)⟩+⟨V(t)⟩+⟨V(t)⟩+⟨R(t)⟩]−(μ1+μ2)[⟨A(t)⟩+⟨I(t)⟩]+σ1t∫t0SdB1(x)+σ2t∫t0EdB2(x)+σ3t∫t0V1dB3(x)+σ4t∫t0V2dB4(x)+σ5t∫t0AdB5(x)+σ6t∫t0IdB6(x)+σ7t∫t0RdB7(x). |
At this time, we have
⟨S(t)⟩=Aμ1−[⟨E(t)⟩+⟨V1(t)⟩+⟨V2(t)⟩+⟨R(t)⟩]−(μ1+μ2)μ1[⟨A(t)⟩+⟨I(t)⟩]+ϕ(t), | (4.6) |
where
ϕ(t)=σ1μ1t∫t0SdB1(x)+σ2μ1t∫t0EdB2(x)+σ3μ1t∫t0V1dB3(x)+σ4μ1t∫t0V2dB4(x)+σ5μ1t∫t0AdB5(x)+σ6μ1t∫t0IdB6(x)+σ7μ1t∫t0RdB7(x)−1μ1[S(t)−S(0)t+E(t)−E(0)t+V1(t)−V1(0)t+V2(t)−V2(0)t]−1μ1[A(t)−A(0)t+I(t)−I(0)t+R(t)−R(0)t]. |
We can also obtained
⟨E(t)⟩=Aμ1−[⟨S(t)⟩+⟨V1(t)⟩+⟨V2(t)⟩+⟨R(t)⟩]−(μ1+μ2)μ1[⟨A(t)⟩+⟨I(t)⟩]+ϕ(t). | (4.7) |
Then, Itˆos formula is used for the fifth formula in Eq (2.2), we can get
dlogA(t)=[(1−ω)σE−(α+γ1+μ1+μ2)A]1Adt−σ252dt+σ5dB5(t). | (4.8) |
Integrate Eq (4.8) from 0 to t:
logA(t)−logA(0)⩽∫t0[(1−ω)σE−(α+γ1+μ1+μ2+σ252)]dt+σ5dB5(t)⩽[(1−ω)σE−(α+γ1+μ1+μ2+σ252)]t+σ5B5(t). | (4.9) |
Substitute Eq (4.7) into Eq (4.9) and divide by t, so there is
logA(t)−logA(0)t⩽(1−ω)σ⟨E(t)⟩−(α+γ1+μ1+μ2+σ252)+σ5B5(t)t⩽(1−ω)σμ1Λ−(μ1+μ2)(1−ω)σμ1⟨A(t)⟩+(1−ω)σϕ(t)−(α+γ1+μ1+μ2+σ252)+σ5B5(t)t⩽(α+γ1+μ1+μ2+σ252)((1−ω)σAμ1(α+γ1+μ1+μ2+σ252)−1)−(μ1+μ2)(1−ω)σμ1⟨A(t)⟩+σ5B5(t)t+φ(t), | (4.10) |
where φ(t)=σ(1−ω)ϕ(t). Rs0 is the called random threshold and it is shown as
Rs0=(1−ω)σAμ1(α+γ1+μ1+μ2+σ252). |
According to the strong number theorem, we have limt→∞B5(t)t=0, i.e., limt→∞σ5B5(t)t=0. Therefore, take the limit on both sides of Eq (4.10) at the same time; we then get
limt→∞suplogA(t)t⩽(α+γ1+μ1+μ2+σ252)(Rs0−1)−(μ1+μ2)(1−ω)σμ1⟨A(t)⟩<0; |
this means that when Rs0<1
limt→∞A(t)=0. | (4.11) |
Taking the limit on both sides of Eq (4.6) at the same time, we can obtain
limt→∞S(t)=Λμ1. | (4.12) |
Set M={ω=Ω:limt→∞S(t)=Λμ1}, which means that P(M)=1 at this point.
From Eq (4.7), we can get
limt→∞⟨E(t)⟩⩽Λμ1. |
For ∀ω∈M,t>0, we can get limt→∞E(ω,t)=0, ω∈M. Considering that P(M)=1, we can obtain
limt→∞E(t)=0,a.s.. | (4.13) |
It can be seen from Eq (4.5) that
I(t)−I(0)t=ωσ⟨E(t)⟩+α⟨A(t)⟩−γ2⟨I((t)⟩−(μ1+μ2)⟨I(t)⟩+σ6t∫t0IdB6(x), |
i.e.
⟨I(t)⟩=1γ2+μ1+μ2[ωσ⟨E(t)⟩+α⟨A(t)⟩−I(t)−I(0)t+σ6t∫t0IdB5(t)]. | (4.14) |
It can be concluded that limt→∞⟨I(t)⟩=0, a.s.
Therefore, this conclusion is proved.
In this section, in order to verify the effects of vaccination and random disturbance on controlling the spread of disease, we used the Milstein method[38,39] to conduct numerical simulations of the stochastic model described by Eq (2.2).
The parameter values of Eq (2.2) are shown in the following table (Table 1).
Parameter | Value | Source |
Λ | 0.03 | |
β1 | 1.038 | |
β2 | 0.083 | |
σ | 15.2 | [40] |
ω | 0.8 | [40] |
α | 0.19 | [40] |
γ1 | 0.3 | [41] |
γ2 | 0.001 | [41] |
μ1 | 0.09 | [41] |
μ2 | 0.001 | [41] |
Eq (2.2) is discretized into the following format:
{Sj=Sj−1+[Λ−(β1Aj−1+β2Ij−1)Sj−1−(μ1+ρ1)Sj−1]Δt+σ1(Sj−1)√Δtζj−1+σ212(Sj−1)(ζ2j−1−1)Δt,Ej=Ej−1+[(β1Aj−1+β2Ij−1)Sj−1+α2β2V2j−1Ij−1−(σ+μ1)Ej−1]Δt+σ2(Ej−1)√Δtζj−1+σ222(Ej−1)(ζ2j−1−1)Δt,V1j=V1j−1+[ρ1Sj−1−(ρ2+μ1)V1j−1]Δt+σ3(V1j−1)√Δtζj−1+σ232(V1j−1)(ζ2j−1−1)Δt,V2j=V2j−1+[ρ2V1j−1−α2β2V2j−1Ij−1−(μ1+1−α2)V2j−1]Δt+σ4(V2j−1)√Δtζj−1+σ242(V2j−1)(ζ2j−1−1)Δt,Aj=Aj−1+[(1−ω)σEj−1−(α+γ1+μ1+μ2)Aj−1]Δt+σ5(Aj−1)√Δtζj−1+σ252(Aj−1)(ζ2j−1−1)Δt,Ij=Ij−1+[ωσEj−1+αAj−1−(γ2+μ1+μ2)Ij−1]Δt+σ6(Ij−1)√Δtζj−1+σ262(Ij−1)(ζ2j−1−1)Δt,Rj=Rj−1+[(1−α2)V2j−1+γ1Aj−1+γ2Ij−1−μ1Rj−1]Δt+σ7(Rj−1)√Δtζj−1+σ272(Rj−1)(ζ2j−1−1)Δt, |
where ζj(j=1,2,⋯,n) are independent Gaussian random variables N(0,1). Based on the parameters in Table 1, the initial value of the numerical experiment was set as (S(0),E(0),V1(0),V2(0),A(0),I(0),R(0))=(0.1,0.1,0,0,0.1,0.2,0).
Based on Table 1, let ρ1=0.9,ρ2=0.9,α2=0.008, σ1=0.15, σ2=0.063, σ3=0.338, σ4=0.068, σ5=0.25, σ6=0.09 and σ7=0.023. The asymptotic behavior of the stochastic model at the disease-free equilibrium point E0=(0.0303,0,0.0275,0.0229,0,0,0.2526) can be shown in Figure 2. At this time, the random threshold is Rs0=0.0209<R0=0.2872<1.
In Figure 2, asymptomatic and symptomatic infections gradually decrease until they disappear, which means that the disease tends to extinction. This is consistent with the previous theoretical results on the extinction of disease. In other words, appropriate noise intensity can promote the extinction of the disease. With the passage of time, the probability of disease extinction becomes 1.
Based on the parameters given in Table 1, ρ1=0.9,α2=0.008 and we let ρ2 equal to 0, 0.5 and 0.9 respectively, the extinction trends of asymptomatic infected person A and symptomatic infected person I are shown in Figure 3(a) and (b). It is clear from Figure 3 that with the increase of the secondary vaccination rate, disease extinction approaches faster. In addition, when ρ1=0.9,ρ2=0.9, the extinction trends of the two infected populations are shown in Figure 3(c) and (d) as α2 is equal to 0.008, 0.025 and 0.05 respectively. We found that the smaller the value of α2 and the higher the vaccine efficiency, the faster the disease tends to extinction. So, we can know from Figure 3 that improving the secondary vaccination rate and vaccine efficiency is one of the important measures to effectively control the epidemic.
According to Theorem 2, σ5 is random intensity acting on asymptomatic infected persons which can directly affect the random threshold Rs0. This means that σ5 can directly affect the speed of the extinction of the disease and that other noise intensity types indirectly affects the extinction of the disease. Therefore the influence of σ5 on the extinction of the disease was mainly investigated. When other noise intensity types are kept constant and σ5 is set to 0, 0.05, 0.15 and 0.25 respectively, the influence of different noise intensities on disease extinction is shown in Figure 4. It can be seen in Figure 4 that the noise intensity can promote the extinction of the infected population. Under the constraint of a random threshold, the higher the noise intensity σ5, the faster the disease-free equilibrium point is reached.
In real life, σ5 represents the disturbance intensity of infected persons under the policies of isolation measures, the effective diagnosis of asymptomatic infected persons and self-protection. From the above analysis, it can be seen that the more complete the intervention policies for infected people, the better the disease prevention and control.
At present, the mathematical modeling of infectious diseases plays an important role in providing epidemic prevention and control strategies. In order to control the epidemic in real life, quarantine and other epidemic prevention measures have been proposed, which have become a random disturbance factor affecting the spread of the epidemic in the infectious disease model. So far, vaccination is considered to be one of the most popular and effective methods to alleviate and prevent epidemics. Based on this, the SEV1V2AIR model was established by considering random disturbance and secondary vaccination, and then the dynamical analysis of the model was carried out. First, using the stop time theory and Lyapunov analysis method, it was proved that the proposed model has a globally unique positive solution. Then, we obtained the theoretical results about the random threshold Rs0. When RS0<1, the disease tends to become extinct. Finally, numerical simulations were performed to verify the theoretical results.
In this paper, the theoretical and numerical simulations show that vaccination and random disturbance have a great impact on disease dynamics. The intensity of the random disturbance directly affects the extinction rate of the infected population. In addition, the higher the secondary vaccination rate and vaccine effectiveness, the faster the extinction rate of the disease. In order to control infectious diseases, we can not only reduce the disease transmission rate through isolation, self-protection and other measures, but also encourage susceptible individuals to get vaccinated and improve the effectiveness of the vaccine. These conclusions provide theoretical basis for preventing and controlling the spread of COVID-19.
Furthmore, the impact of some discontinuous factors and vaccine frequency on COVID-19 will be discussed in the future work because of more influential disturbances, such as large-scale human aggregation, the promotion of antiviral drugs and so on.
This work was supported by grants from the National Natural Science Foundation of China (No. 11772002), Ningxia higher education first-class discipline construction funding project (NXYLXK2017B09), Major special project of North Minzu University (No. ZDZX201902), Open project of The Key Laboratory of Intelligent Information and Big Data Processing of NingXia Province (No. 2019KLBD008) and Postgraduate innovation project of North Minzu University (YCX22099). The authors would like to thank the editors and reviewers for their valuable suggestions on the logic and preciseness of this article.
The authors declare that there is no conflict of interest.
[1] | Goncalves FA, Colen G, Takahashi JA (2014) Yarrowia lipolytica and its multiple applications in the biotechnological industry. Sci World J 2014: 476207. |
[2] |
Zhu Q, Jackson EN (2015) Metabolic engineering of Yarrowia lipolytica for industrial applications. Curr Opin Biotechnol 36: 65–72. doi: 10.1016/j.copbio.2015.08.010
![]() |
[3] |
Cordero Otero R, Gaillardin C (1996) Efficient selection of hygromycin-B-resistant Yarrowia lipolytica transformants. Appl Microbiol Biotechnol 46: 143–148. doi: 10.1007/s002530050796
![]() |
[4] |
Chen DC, Beckerich JM, Gaillardin C (1997) One-step transformation of the dimorphic yeast Yarrowia lipolytica. Appl Microbiol Biotechnol 48: 232–235. doi: 10.1007/s002530051043
![]() |
[5] | Liu L, Otoupal P, Pan A, et al. (2014) Increasing expression level and copy number of a Yarrowia lipolytica plasmid through regulated centromere function. FEMS Yeast Res 14: 1124–1127. |
[6] |
Hussain MS, Gambill L, Smith S, et al. (2016) Engineering promoter architecture in oleaginous yeast Yarrowia lipolytica. ACS Synth Biol 5: 213–223. doi: 10.1021/acssynbio.5b00100
![]() |
[7] |
Blazeck J, Reed B, Garg R, et al. (2013) Generalizing a hybrid synthetic promoter approach in Yarrowia lipolytica. Appl Microbiol Biotechnol 97: 3037–3052. doi: 10.1007/s00253-012-4421-5
![]() |
[8] |
Blazeck J, Liu L, Redden H, et al. (2011) Tuning gene expression in Yarrowia lipolytica by a hybrid promoter approach. Appl Environ Microbiol 77: 7905–7914. doi: 10.1128/AEM.05763-11
![]() |
[9] | Schwartz CM, Hussain MS, Blenner M, et al. (2016) Synthetic RNA polymerase III promoters facilitate high-efficiency CRISPR-Cas9-mediated genome editing in Yarrowia lipolytica. ACS Synth Biol. |
[10] | Blazeck J, Hill A, Liu L, et al. (2014) Harnessing Yarrowia lipolytica lipogenesis to create a platform for lipid and biofuel production. Nat Commun 5: 3131. |
[11] |
Tai M, Stephanopoulos G (2013) Engineering the push and pull of lipid biosynthesis in oleaginous yeast Yarrowia lipolytica for biofuel production. Metab Eng 15: 1–9. doi: 10.1016/j.ymben.2012.08.007
![]() |
[12] |
Qiao K, Imam Abidi SH, Liu H, et al. (2015) Engineering lipid overproduction in the oleaginous yeast Yarrowia lipolytica. Metab Eng 29: 56–65. doi: 10.1016/j.ymben.2015.02.005
![]() |
[13] |
Xu P, Qiao KJ, Ahn WS, et al. (2016) Engineering Yarrowia lipolytica as a platform for synthesis of drop-in transportation fuels and oleochemicals. P Natl Acad Sci USA 113: 10848–10853. doi: 10.1073/pnas.1607295113
![]() |
[14] |
Friedlander J, Tsakraklides V, Kamineni A, et al. (2016) Engineering of a high lipid producing Yarrowia lipolytica strain. Biotechnol Biofuels 9: 77. doi: 10.1186/s13068-016-0492-3
![]() |
[15] |
Xue Z, Sharpe PL, Hong SP, et al. (2013) Production of omega-3 eicosapentaenoic acid by metabolic engineering of Yarrowia lipolytica. Nat Biotechnol 31: 734–740. doi: 10.1038/nbt.2622
![]() |
[16] |
Smit MS, Mokgoro MM, Setati E, et al. (2005) alpha,omega-Dicarboxylic acid accumulation by acyl-CoA oxidase deficient mutants of Yarrowia lipolytica. Biotechnol Lett 27: 859–864. doi: 10.1007/s10529-005-6719-1
![]() |
[17] |
Haddouche R, Poirier Y, Delessert S, et al. (2011) Engineering polyhydroxyalkanoate content and monomer composition in the oleaginous yeast Yarrowia lipolytica by modifying the ss-oxidation multifunctional protein. Appl Microbiol Biotechnol 91: 1327–1340. doi: 10.1007/s00253-011-3331-2
![]() |
[18] |
Blazeck J, Hill A, Jamoussi M, et al. (2015) Metabolic engineering of Yarrowia lipolytica for itaconic acid production. Metab Eng 32: 66–73. doi: 10.1016/j.ymben.2015.09.005
![]() |
[19] |
Ledesma-Amaro R, Dulermo R, Niehus X, et al. (2016) Combining metabolic engineering and process optimization to improve production and secretion of fatty acids. Metab Eng 38: 38–46. doi: 10.1016/j.ymben.2016.06.004
![]() |
[20] |
Zhou J, Yin X, Madzak C, et al. (2012) Enhanced alpha-ketoglutarate production in Yarrowia lipolytica WSH-Z06 by alteration of the acetyl-CoA metabolism. J Biotechnol 161: 257–264. doi: 10.1016/j.jbiotec.2012.05.025
![]() |
[21] |
Yovkova V, Otto C, Aurich A, et al. (2014) Engineering the alpha-ketoglutarate overproduction from raw glycerol by overexpression of the genes encoding NADP+-dependent isocitrate dehydrogenase and pyruvate carboxylase in Yarrowia lipolytica. Appl Microbiol Biotechnol 98: 2003–2013. doi: 10.1007/s00253-013-5369-9
![]() |
[22] |
Wang G, Xiong X, Ghogare R, et al. (2016) Exploring fatty alcohol-producing capability of Yarrowia lipolytica. Biotechnol Biofuels 9: 107. doi: 10.1186/s13068-016-0512-3
![]() |
[23] |
Rutter CD, Rao CV (2016) Production of 1-decanol by metabolically engineered Yarrowia lipolytica. Metab Eng 38: 139–147. doi: 10.1016/j.ymben.2016.07.011
![]() |
[24] |
Wang W, Wei H, Knoshaug E, et al. (2016) Fatty alcohol production in Lipomyces starkeyi and Yarrowia lipolytica. Biotechnol Biofuels 9: 227. doi: 10.1186/s13068-016-0647-2
![]() |
[25] | Ryu S, Hipp J, Trinh CT (2015) Activating and elucidating metabolism of complex sugars in Yarrowia lipolytica. Appl Environ Microbiol 82: 1334–1345. |
[26] |
Rodriguez GM, Hussain MS, Gambill L, et al. (2016) Engineering xylose utilization in Yarrowia lipolytica by understanding its cryptic xylose pathway. Biotechnol Biofuels 9: 149. doi: 10.1186/s13068-016-0562-6
![]() |
[27] |
Ledesma-Amaro R, Nicaud JM (2016) Metabolic engineering for expanding the substrate range of Yarrowia lipolytica. Trends Biotechnol 34: 798–809. doi: 10.1016/j.tibtech.2016.04.010
![]() |
[28] |
Li H, Alper HS (2016) Enabling xylose utilization in Yarrowia lipolytica for lipid production. Biotechnol J 11: 1230–1240. doi: 10.1002/biot.201600210
![]() |
[29] |
Ledesma-Amaro R, Lazar Z, Rakicka M, et al. (2016) Metabolic engineering of Yarrowia lipolytica to produce chemicals and fuels from xylose. Metab Eng 38: 115–124. doi: 10.1016/j.ymben.2016.07.001
![]() |
[30] |
Ledesma-Amaro R, Dulermo T, Nicaud JM (2015) Engineering Yarrowia lipolytica to produce biodiesel from raw starch. Biotechnol Biofuels 8: 148. doi: 10.1186/s13068-015-0335-7
![]() |
[31] |
Celinska E, Bialas W, Borkowska M, et al. (2015) Cloning, expression, and purification of insect (Sitophilus oryzae) alpha-amylase, able to digest granular starch, in Yarrowia lipolytica host. Appl Microbiol Biotechnol 99: 2727–2739. doi: 10.1007/s00253-014-6314-2
![]() |
[32] |
Yang CH, Huang YC, Chen CY, et al. (2010) Heterologous expression of Thermobifida fusca thermostable alpha-amylase in Yarrowia lipolytica and its application in boiling stable resistant sago starch preparation. J Ind Microbiol Biotechnol 37: 953–960. doi: 10.1007/s10295-010-0745-2
![]() |
[33] |
Xu J, Xiong P, He B (2016) Advances in improving the performance of cellulase in ionic liquids for lignocellulose biorefinery. Bioresour Technol 200: 961–970. doi: 10.1016/j.biortech.2015.10.031
![]() |
[34] |
Dujon B, Sherman D, Fischer G, et al. (2004) Genome evolution in yeasts. Nature 430: 35–44. doi: 10.1038/nature02579
![]() |
[35] | Liu L, Alper HS (2014) Draft genome sequence of the oleaginous yeast Yarrowia lipolytica PO1f, a commonly used metabolic engineering host. Genome Announc 2. |
[36] |
Magnan C, Yu J, Chang I, et al. (2016) Sequence assembly of Yarrowia lipolytica strain W29/CLIB89 shows transposable element diversity. PLoS One 11: e0162363. doi: 10.1371/journal.pone.0162363
![]() |
[37] |
van Heerikhuizen H, Ykema A, Klootwijk J, et al. (1985) Heterogeneity in the ribosomal RNA genes of the yeast Yarrowia lipolytica; cloning and analysis of two size classes of repeats. Gene 39: 213–222. doi: 10.1016/0378-1119(85)90315-4
![]() |
[38] |
Davidow LS, Apostolakos D, O’Donnell MM, et al. (1985) Integrative transformation of the yeast Yarrowia lipolytica. Curr Genet 10: 39–48. doi: 10.1007/BF00418492
![]() |
[39] | Barth G, Gaillardin C (1996) Yarrowia lipolytica, In: Wolf K, Nonconventional Yeasts in Biotechnology, NewYork: Springer. |
[40] |
Wang JH, Hung W, Tsai SH (2011) High efficiency transformation by electroporation of Yarrowia lipolytica. J Microbiol 49: 469–472. doi: 10.1007/s12275-011-0433-6
![]() |
[41] |
Duquesne S, Bordes F, Fudalej F, et al. (2012) The yeast Yarrowia lipolytica as a generic tool for molecular evolution of enzymes. Methods Mol Biol 861: 301–312. doi: 10.1007/978-1-61779-600-5_18
![]() |
[42] |
Theerachat M, Emond S, Cambon E, et al. (2012) Engineering and production of laccase from Trametes versicolor in the yeast Yarrowia lipolytica. Bioresour Technol 125: 267–274. doi: 10.1016/j.biortech.2012.07.117
![]() |
[43] |
Juretzek T, Wang HJ, Nicaud JM, et al. (2000) Comparison of promoters suitable for regulated overexpression of β-galactosidase in the alkane-utilizing yeast Yarrowia lipolytica. Biotechnol Bioproc Eng 5: 320–326. doi: 10.1007/BF02942206
![]() |
[44] | Wang HJ, Le Dall MT, Wach Y, et al. (1999) Evaluation of acyl coenzyme A oxidase (Aox) isozyme function in the n-alkane-assimilating yeast Yarrowia lipolytica. J Bacteriol 181: 5140–5148. |
[45] |
Yamagami S, Morioka D, Fukuda R, et al. (2004) A basic helix-loop-helix transcription factor essential for cytochrome p450 induction in response to alkanes in yeast Yarrowia lipolytica. J Biol Chem 279: 22183–22189. doi: 10.1074/jbc.M313313200
![]() |
[46] |
Blanchin-Roland S, Cordero Otero RR, Gaillardin C (1994) Two upstream activation sequences control the expression of the XPR2 gene in the yeast Yarrowia lipolytica. Mol Cell Biol 14: 327–338. doi: 10.1128/MCB.14.1.327
![]() |
[47] | Madzak C, Blanchin-Roland S, Cordero Otero RR, et al. (1999) Functional analysis of upstream regulating regions from the Yarrowia lipolytica XPR2 promoter. Microbiology 145 (Pt 1): 75–87. |
[48] | Madzak C, Treton B, Blanchin-Roland S (2000) Strong hybrid promoters and integrative expression/secretion vectors for quasi-constitutive expression of heterologous proteins in the yeast Yarrowia lipolytica. J Mol Microbiol Biotechnol 2: 207–216. |
[49] |
Shabbir Hussain M, Gambill L, Smith S, et al. (2016) Engineering promoter architecture in oleaginous yeast Yarrowia lipolytica. ACS Synth Biol 5: 213–223. doi: 10.1021/acssynbio.5b00100
![]() |
[50] | Muller S, Sandal T, Kamp-Hansen P, et al. (1998) Comparison of expression systems in the yeasts Saccharomyces cerevisiae, Hansenula polymorpha, Klyveromyces lactis, Schizosaccharomyces pombe and Yarrowia lipolytica. Cloning of two novel promoters from Yarrowia lipolytica. Yeast 14: 1267–1283. |
[51] |
Kozak M (1984) Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 12: 857–872. doi: 10.1093/nar/12.2.857
![]() |
[52] |
Kozak M (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283–292. doi: 10.1016/0092-8674(86)90762-2
![]() |
[53] | Merkulov S, van Assema F, Springer J, et al. (2000) Cloning and characterization of the Yarrowia lipolytica squalene synthase (SQS1) gene and functional complementation of the Saccharomyces cerevisiae erg9 mutation. Yeast 16: 197–206. |
[54] |
Zhang B, Rong C, Chen H, et al. (2012) De novo synthesis of trans-10, cis-12 conjugated linoleic acid in oleaginous yeast Yarrowia lipolytica. Microb Cell Fact 11: 1–8. doi: 10.1186/1475-2859-11-1
![]() |
[55] |
Kramara J, Willcox S, Gunisova S, et al. (2010) Tay1 protein, a novel telomere binding factor from Yarrowia lipolytica. J Biol Chem 285: 38078–38092. doi: 10.1074/jbc.M110.127605
![]() |
[56] | Farrel C, Mayorga M, Chevreux B (2013) Carotene hydroxylase and its use for producing carotenoids. In: Ltd DNP. |
[57] |
Gasmi N, Fudalej F, Kallel H, et al. (2011) A molecular approach to optimize hIFN alpha2b expression and secretion in Yarrowia lipolytica. Appl Microbiol Biotechnol 89: 109–119. doi: 10.1007/s00253-010-2803-0
![]() |
[58] | Nakagawa S, Niimura Y, Gojobori T, et al. (2008) Diversity of preferred nucleotide sequences around the translation initiation codon in eukaryote genomes. Nucleic Acids Res 36: 861–871. |
[59] |
Schwartz CM, Hussain MS, Blenner M, et al. (2016) Synthetic RNA Polymerase III Promoters Facilitate High-Efficiency CRISPR-Cas9-Mediated Genome Editing in Yarrowia lipolytica. ACS Synth Biol 5: 356–359. doi: 10.1021/acssynbio.5b00162
![]() |
[60] |
Gao S, Han L, Zhu L, et al. (2014) One-step integration of multiple genes into the oleaginous yeast Yarrowia lipolytica. Biotechnol Lett 36: 2523–2528. doi: 10.1007/s10529-014-1634-y
![]() |
[61] |
Curran KA, Morse NJ, Markham KA, et al. (2015) Short synthetic terminators for improved heterologous gene expression in yeast. ACS Synth Biol 4: 824–832. doi: 10.1021/sb5003357
![]() |
[62] |
Laine JP, Singh BN, Krishnamurthy S, et al. (2009) A physiological role for gene loops in yeast. Genes Dev 23: 2604–2609. doi: 10.1101/gad.1823609
![]() |
[63] |
Kanaar R, Hoeijmakers JH, van Gent DC (1998) Molecular mechanisms of DNA double strand break repair. Trends Cell Biol 8: 483–489. doi: 10.1016/S0962-8924(98)01383-X
![]() |
[64] |
Pastink A, Lohman PH (1999) Repair and consequences of double-strand breaks in DNA. Mutat Res 428: 141–156. doi: 10.1016/S1383-5742(99)00042-3
![]() |
[65] | Pastink A, Eeken JC, Lohman PH (2001) Genomic integrity and the repair of double-strand DNA breaks. Mutat Res 480: 37–50. |
[66] |
Loeillet S, Palancade B, Cartron M, et al. (2005) Genetic network interactions among replication, repair and nuclear pore deficiencies in yeast. DNA Repair (Amst) 4: 459–468. doi: 10.1016/j.dnarep.2004.11.010
![]() |
[67] |
Fickers P, Le Dall MT, Gaillardin C, et al. (2003) New disruption cassettes for rapid gene disruption and marker rescue in the yeast Yarrowia lipolytica. J Microbiol Methods 55: 727–737. doi: 10.1016/j.mimet.2003.07.003
![]() |
[68] |
Van Dyck E, Stasiak AZ, Stasiak A, et al. (1999) Binding of double-strand breaks in DNA by human Rad52 protein. Nature 398: 728–731. doi: 10.1038/19560
![]() |
[69] |
Verbeke J, Beopoulos A, Nicaud JM (2013) Efficient homologous recombination with short length flanking fragments in Ku70 deficient Yarrowia lipolytica strains. Biotechnol Lett 35: 571–576. doi: 10.1007/s10529-012-1107-0
![]() |
[70] |
Kretzschmar A, Otto C, Holz M, et al. (2013) Increased homologous integration frequency in Yarrowia lipolytica strains defective in non-homologous end-joining. Curr Genet 59: 63–72. doi: 10.1007/s00294-013-0389-7
![]() |
[71] | Vasiliki T, Elena B, Gregory S, et al. (2015) Improved gene targeting through cell cycle synchronization. PLoS One 10. |
[72] | Isaac RS, Jiang F, Doudna JA, et al. (2016) Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. Elife 5. |
[73] | Daer R, Cutts JP, Brafman DA, et al. (2016) The impact of chromatin dynamics on Cas9-mediated genome editing in human cells. ACS Synth Biol. |
[74] | Hamilton DL, Abremski K (1984) Site-specific recombination by the bacteriophage P1 lox-Cre system. Cre-mediated synapsis of two lox sites. J Mol Biol 178: 481–486. |
[75] |
Le Dall MT, Nicaud JM, Gaillardin C (1994) Multiple-copy integration in the yeast Yarrowia lipolytica. Curr Genet 26: 38–44. doi: 10.1007/BF00326302
![]() |
[76] |
Casaregola S, Feynerol C, Diez M, et al. (1997) Genomic organization of the yeast Yarrowia lipolytica. Chromosoma 106: 380–390. doi: 10.1007/s004120050259
![]() |
[77] |
Schmid-Berger N, Schmid B, Barth G (1994) Ylt1, a highly repetitive retrotransposon in the genome of the dimorphic fungus Yarrowia lipolytica. J Bacteriol 176: 2477–2482. doi: 10.1128/jb.176.9.2477-2482.1994
![]() |
[78] |
Mauersberger S, Wang HJ, Gaillardin C, et al. (2001) Insertional mutagenesis in the n-alkane-assimilating yeast Yarrowia lipolytica: generation of tagged mutations in genes involved in hydrophobic substrate utilization. J Bacteriol 183: 5102–5109. doi: 10.1128/JB.183.17.5102-5109.2001
![]() |
[79] |
Bordes F, Fudalej F, Dossat V, et al. (2007) A new recombinant protein expression system for high-throughput screening in the yeast Yarrowia lipolytica. J Microbiol Meth 70: 493–502. doi: 10.1016/j.mimet.2007.06.008
![]() |
[80] |
Pignede G, Wang HJ, Fudalej F, et al. (2000) Autocloning and amplification of LIP2 in Yarrowia lipolytica. Appl Environ Microbiol 66: 3283–3289. doi: 10.1128/AEM.66.8.3283-3289.2000
![]() |
[81] | Nicaud JM, Madzak C, van den Broek P, et al. (2002) Protein expression and secretion in the yeast Yarrowia lipolytica. FEMS Yeast Res 2: 371–379. |
[82] |
Gao C, Qi Q, Madzak C, et al. (2015) Exploring medium-chain-length polyhydroxyalkanoates production in the engineered yeast Yarrowia lipolytica. J Ind Microbiol Biotechnol 42: 1255–1262. doi: 10.1007/s10295-015-1649-y
![]() |
[83] |
Ratledge C (2002) Regulation of lipid accumulation in oleaginous micro-organisms. Biochem Soc Trans 30: 1047–1050. doi: 10.1042/bst0301047
![]() |
[84] |
Beopoulos A, Cescut J, Haddouche R, et al. (2009) Yarrowia lipolytica as a model for bio-oil production. Prog Lipid Res 48: 375–387. doi: 10.1016/j.plipres.2009.08.005
![]() |
[85] |
Ratledge C (2014) The role of malic enzyme as the provider of NADPH in oleaginous microorganisms: a reappraisal and unsolved problems. Biotechnol Lett 36: 1557–1568. doi: 10.1007/s10529-014-1532-3
![]() |
[86] |
Wynn JP, Kendrick A, Hamid AA, et al. (1997) Malic enzyme: a lipogenic enzyme in fungi. Biochem Soc Trans 25: S669. doi: 10.1042/bst025s669
![]() |
[87] |
Zhang H, Zhang L, Chen H, et al. (2013) Regulatory properties of malic enzyme in the oleaginous yeast, Yarrowia lipolytica, and its non-involvement in lipid accumulation. Biotechnol Lett 35: 2091–2098. doi: 10.1007/s10529-013-1302-7
![]() |
[88] |
Wasylenko TM, Ahn WS, Stephanopoulos G (2015) The oxidative pentose phosphate pathway is the primary source of NADPH for lipid overproduction from glucose in Yarrowia lipolytica. Metab Eng 30: 27–39. doi: 10.1016/j.ymben.2015.02.007
![]() |
[89] |
Liu N, Qiao K, Stephanopoulos G (2016) 13C Metabolic Flux Analysis of acetate conversion to lipids by Yarrowia lipolytica. Metab Eng 38: 86–97. doi: 10.1016/j.ymben.2016.06.006
![]() |
[90] |
Morin N, Cescut J, Beopoulos A, et al. (2011) Transcriptomic analyses during the transition from biomass production to lipid accumulation in the oleaginous yeast Yarrowia lipolytica. PLoS One 6: e27966. doi: 10.1371/journal.pone.0027966
![]() |
[91] |
Beopoulos A, Mrozova Z, Thevenieau F, et al. (2008) Control of lipid accumulation in the yeast Yarrowia lipolytica. Appl Environ Microbiol 74: 7779–7789. doi: 10.1128/AEM.01412-08
![]() |
[92] | Beopoulos A, Haddouche R, Kabran P, et al. (2012) Identification and characterization of DGA2, an acyltransferase of the DGAT1 acyl-CoA:diacylglycerol acyltransferase family in the oleaginous yeast Yarrowia lipolytica. New insights into the storage lipid metabolism of oleaginous yeasts. Appl Microbiol Biotechnol 93: 1523–1537. |
[93] |
Wang ZP, Xu HM, Wang GY, et al. (2013) Disruption of the MIG1 gene enhances lipid biosynthesis in the oleaginous yeast Yarrowia lipolytica ACA-DC 50109. Biochim Biophys Acta 1831: 675–682. doi: 10.1016/j.bbalip.2012.12.010
![]() |
[94] |
Seip J, Jackson R, He H, et al. (2013) Snf1 is a regulator of lipid accumulation in Yarrowia lipolytica. Appl Environ Microbiol 79: 7360–7370. doi: 10.1128/AEM.02079-13
![]() |
[95] |
Dulermo T, Nicaud JM (2011) Involvement of the G3P shuttle and beta-oxidation pathway in the control of TAG synthesis and lipid accumulation in Yarrowia lipolytica. Metab Eng 13: 482–491. doi: 10.1016/j.ymben.2011.05.002
![]() |
[96] |
Liu L, Pan A, Spofford C, et al. (2015) An evolutionary metabolic engineering approach for enhancing lipogenesis in Yarrowia lipolytica. Metab Eng 29: 36–45. doi: 10.1016/j.ymben.2015.02.003
![]() |
[97] |
Liu L, Markham K, Blazeck J, et al. (2015) Surveying the lipogenesis landscape in Yarrowia lipolytica through understanding the function of a Mga2p regulatory protein mutant. Metab Eng 31: 102–111. doi: 10.1016/j.ymben.2015.07.004
![]() |
[98] |
Poirier Y, Antonenkov VD, Glumoff T, et al. (2006) Peroxisomal beta-oxidation—a metabolic pathway with multiple functions. Biochim Biophys Acta 1763: 1413–1426. doi: 10.1016/j.bbamcr.2006.08.034
![]() |
[99] |
Dulermo R, Gamboa-Melendez H, Ledesma-Amaro R, et al. (2015) Unraveling fatty acid transport and activation mechanisms in Yarrowia lipolytica. Biochim Biophys Acta 1851: 1202–1217. doi: 10.1016/j.bbalip.2015.04.004
![]() |
[100] |
Haddouche R, Delessert S, Sabirova J, et al. (2010) Roles of multiple acyl-CoA oxidases in the routing of carbon flow towards beta-oxidation and polyhydroxyalkanoate biosynthesis in Yarrowia lipolytica. FEMS Yeast Res 10: 917–927. doi: 10.1111/j.1567-1364.2010.00670.x
![]() |
[101] |
Hazer B, Steinbuchel A (2007) Increased diversification of polyhydroxyalkanoates by modification reactions for industrial and medical applications. Appl Microbiol Biotechnol 74: 1–12. doi: 10.1007/s00253-006-0732-8
![]() |
[102] |
Rehm BH (2003) Polyester synthases: natural catalysts for plastics. Biochem J 376: 15–33. doi: 10.1042/bj20031254
![]() |
[103] |
Sabirova JS, Haddouche R, Van Bogaert I, et al. (2011) The “LipoYeasts” project: using the oleaginous yeast Yarrowia lipolytica in combination with specific bacterial genes for the bioconversion of lipids, fats and oils into high-value products. Microb Biotechnol 4: 47–54. doi: 10.1111/j.1751-7915.2010.00187.x
![]() |
[104] |
Chuah JA, Tomizawa S, Yamada M, et al. (2013) Characterization of site-specific mutations in a short-chain-length/medium-chain-length polyhydroxyalkanoate synthase: in vivo and in vitro studies of enzymatic activity and substrate specificity. Appl Environ Microbiol 79: 3813–3821. doi: 10.1128/AEM.00564-13
![]() |
[105] |
Tsigie YA, Wang CY, Truong CT, et al. (2011) Lipid production from Yarrowia lipolytica Po1g grown in sugarcane bagasse hydrolysate. Bioresour Technol 102: 9216–9222. doi: 10.1016/j.biortech.2011.06.047
![]() |
[106] |
Ruiz-Herrera J, Sentandreu R (2002) Different effectors of dimorphism in Yarrowia lipolytica. Arch Microbiol 178: 477–483. doi: 10.1007/s00203-002-0478-3
![]() |
[107] | Fontes GC, Amaral PF, Nele M, et al. (2010) Factorial design to optimize biosurfactant production by Yarrowia lipolytica. J Biomed Biotechnol 2010: 821306. |
[108] | Pan LX, Yang DF, Shao L, et al. (2009) Isolation of the oleaginous yeasts from the soil and studies of their lipid-producing capacities. Food Technol Biotechnol 47: 215–220. |
1. | Liqiong Jian, Xinyu Bai, Shaojuan Ma, Minyu Feng, Stochastic dynamical analysis for the complex infectious disease model driven by multisource noises, 2024, 19, 1932-6203, e0296183, 10.1371/journal.pone.0296183 | |
2. | Rujie Yang, Hong Qiu, A Valid Transport Related SVEIHR Stochastic Epidemic Model with Coverage and Time Delays, 2024, 23, 2224-2880, 815, 10.37394/23206.2024.23.84 | |
3. | Munkaila Dasumani, Sianou Ezéckiel Houénafa, Gohouede Lionel Cédric, Binandam S. Lassong, Stephen E. Moore, Deterministic and stochastic models for analyzing the dynamics of diabetes mellitus, 2025, 26668181, 101202, 10.1016/j.padiff.2025.101202 |